A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy

Trial Profile

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms OAK
  • Sponsors Roche
  • Most Recent Events

    • 05 Jun 2018 Results of a large retrospective analysis associating tTMB with neoantigen load and efficacy using pooled data from multiple studies (FIR, BIRCH, POPLAR, OAK; NSCLC n= 342), (IMvigor210, 211; metastatic urothelial carcinoma n=400) and (PCD4989g; other advanced solid tumors n=245), presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results (n=1720) of preliminary data of pooled analysis (CA209057, the KEYNOTE-010 and the OAK trial) assessing the role of immunotherapy for second line treatment of advanced, pre-treated, non-squamous Non-small-cell-lung-cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 16 May 2018 Results published in the Journal of Thoracic Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top